Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease

Objective: To test whether higher global functional connectivity of the left frontal cortex (LFC) in Alzheimer disease (AD) is associated with more years of education (a proxy of cognitive reserve [CR]) and mitigates the association between AD-related fluorodeoxyglucose (FDG)-PET hypometabolism and episodic memory.

Methods: Forty-four amyloid-PET–positive patients with amnestic mild cognitive impairment (MCI-Aβ+) and 24 amyloid-PET–negative healthy controls (HC) were included.

Doctor Tuchman’s Interview on Dementia with Lewy Bodies

Dr. Michael Tuchman was recently interviewed by the Palm Beach Post in regards to dementia with Lewy Bodies, or “DLB,” the effects it has and how it affected a Palm Beach Gardens couple. DLB is caused by the buildup of protein clusters in the brain and symptoms include rapid mood swings, insomnia and nightmares, hallucinations and memory loss.

Aerobic Exercise Found to Improve Cognition in Mild Vascular Cognitive Impairment

Investigators reported that, in a randomized controlled trial, patients with vascular cognitive impairment showed improvement on cognitive tests after participating in a six-month exercise program. Independent experts said the findings were promising, but preliminary.

Progressive aerobic-exercise training for six months appeared to improve cognition in adults with mild subcortical ischemic vascular cognitive impairment,

Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases

Objective: To determine whether cognitive impairment in Parkinson disease (PD) and Alzheimer disease (AD) derives from the same network pathology.

Methods: We analyzed 18F-fluorodeoxyglucose PET scans from 40 patients with AD and 40 age-matched healthy controls from the Alzheimer’s Disease Neuroimaging Initiative and scanned an additional 10 patients with AD and 10 healthy controls at The Feinstein Institute for Medical Research to derive an AD-related metabolic pattern (ADRP) analogous to our previously established PD cognition-related pattern (PDCP) and PD motor-related pattern (PDRP).

Potential Treatment for Early Onset Alzheimer’s…Currently Enrolling

Description

A global clinical research study assessing the effectiveness and safety of an investigational medication designed to slow the progression of early Alzheimer’s disease.

The ENGAGE study is split into two phases: a placebo-controlled phase, and an optional long-term extension phase.

In the placebo-controlled phase, eligible participants will have a 2-in-3 chance of receiving the investigational medication and a 1-in-3 chance of receiving the placebo.

Nerve sonography to detect peripheral nerve involvement in vasculitis syndromes

Background: We sought to determine the usefulness of sonography in the detection of nerve involvement in patients with vasculitic neuropathy.

 

Methods: We enrolled 16 consecutive patients with vasculitic neuropathy (11 systemic vasculitis and 5 single organ peripheral nerve vasculitis), who met the diagnostic criteria of the Peripheral Nerve Society,

Rapid screening for inflammatory neuropathies by standardized clinical criteria

Background: Delay in recognition and treatment of inflammatory neuropathies increases morbidity and mortality. We have developed and standardized 3 clinical screening criteria that rapidly detect inflammatory neuropathies.

 

Methods: We reviewed all patients with definite large fiber neuropathy in 2 different patient populations: 1 from a private neurology clinic and the other from a tertiary care center.

Frequent Migraine Prevention Study…Ongoing Study

Description

A study to evaluate an investigational drug designed to inhibit receptors that are believed to contribute to migraine attacks.

This study lasts up to 55 weeks, in which participants will be screened, go through two phases of treatment and have a follow-up visit.

Study Treatment Phase – Part One – 12 Weeks

Participants will be randomly assigned to receive the investigational drug or a placebo.

Optic neuropathy associated with systemic sarcoidosis

Objective: To identify and follow a series of 52 patients with optic neuropathy related to sarcoidosis.

Demographics.

Fifty-two patients were included in the study. The mean (range) age was 42.5 (20–71) years. Thirty-two (61%) were women. Twenty-four were Caucasian, 24 African or Caribbean, and 4 were from South Asia.

Methods: Prospective observational cohort study.

Clinical manifestations of intermediate allele carriers in Huntington disease

Objective: There is controversy about the clinical consequences of intermediate alleles (IAs) in Huntington disease (HD). The main objective of this study was to establish the clinical manifestations of IA carriers for a prospective, international, European HD registry.

Methods: We assessed a cohort of participants at risk with <36 CAG repeats of the huntingtin (HTT) gene.